|
A study of bacteriology. arch otolaryngol head neck surg . may 1991; 117 5 ; : 538-41. . myer cm 3rd, cotton rt. historical development of surgery for pediatric laryngeal stenosis. ear nose throat j . aug 1995; 74 8 ; : 560-2, 564. . myer cm 3rd, o''connor dm, cotton rt. proposed grading system for subglottic stenosis based on endotracheal tube sizes. ann otol rhinol laryngol . apr 1994; 103 4 pt 1 ; 319-23. . ochi jw, seid ab, pransky sm. an approach to the failed cricoid split operation. int j pediatr otorhinolaryngol . dec 1987; 14 2-3 ; : 229-34. . perepelitsyn i, shapshay sm. endoscopic treatment of laryngeal and tracheal stenosis-has mitomycin c improved the outcome.
Refinements. In addition, each touch of the screen was logged, and the approximately eight weeks of data gathered still needs to be analysed. Currently, the database is only capable of examining information at 20-year intervals known as a static or time-slice approach ; . Initial plans have been developed to add a fourth dimension to the database software C y date-stamping the entities ; so that changes b can be visualised dynamically across time known as a temporal or dynamic approach ; . Development of the tools to do this is well underway. This is a data set covering the built environment in one particular city in North America during one period the 18th century ; . We can expect the eventual creation of many other such data sets covering this and other cities at various points in time. Indeed, the MRG is seeking funding to expand the information in the database to include both earlier and later time periods. ; It is likely that, at least in the immediate future, most of these data sets like MRG ; will use Arc Info software as the underlying base for 2 dimensional mapping, making both the learning skills transferable from one set to another, and making it easier to tie independent sets to one another. Imagine urban historians being able to examine the growth of different cities over the same period of time from their own desktops. The possibilities for comparative studies are only limited by the number of data sets and the lack of standardisation between them. As standards develop, inroads need to be made with governmental agencies, allowing contemporary sets of information to be linked in such a way as to provide similar access to built environment information of the recent past, and to assure future scholars access to information from today without combing through disparate records. We need to be working with records managers from city planning agencies as well as census bureaus and even newsgathering agencies, to assure that future generations will have access to the tools to analyse our contemporary society.
The replication of vaccinia virus is thought to take place exclusively in the cytoplasm of host cells. However, using DNA-DNA hybridization techniques, it can be shown that a significant fraction of the synthesis of vaccinia DNA takes place in the nucleus as well as the cytoplasm. The [3H ]thymidine pulse-labeled vaccinia DNA synthesized in the nucleus reaches a maximum at about 3 h after infection, corresponding to the time of maximal DNA synthesis in infected cells. At this time host DNA synthesis drops to about 25% of the rate of the uninfected cells. Even with short labeling times 2 min ; the nucleus is found to contain 60% of the incorporated [3H]thymidine, much of which is in vaccinia DNA. Prior inhibition of host nuclear DNA synthesis with mitomycin C, followed by removal of the antibiotic, causes a subsequent inhibition of vaccinia DNA synthesis and complete suppression of mature virus. Purified nuclei, isolated from vacciniainfected cells, also synthesize vaccinia DNA in vitro. Over 90% of the DNA synthesized in vitro by isolated nuclei contain vaccinia-specific sequences. The examination of vaccinia-infected cells by autoradiography 4 ; and fluorescent antibody staining 20 ; indicated that vaccinia DNA replicates and virions undergo maturation in large cytoplasmic aggregates factories ; . Subsequently, Joklik and Becker 16 ; demonstrated that the replicating viral DNA, as well as the parental viral DNA, is associated with large cytoplasmic structures which are presumably the same as the vaccinia virosomes identified by autoradiography and electron microscope studies. It is from these factories, starting at 3 to postinfection, that progressively increasing amounts of viral DNA are released and become combined with the viral core and coat proteins. Dahl and Kates 6, 7 ; extended these studies by determining the sedimentation and the density characteristics of parental and newly replicated vaccinia DNA. They showed that the isolated cytoplasmic viral DNA-protein complexes synthesize mRNA sequences with an endogenous RNA polymerase. The mRNA synthesized in vitro is either "early" or "early and late" in accordance with the time of virosome isolation, i.e., before or after vaccinia DNA synthesis has commenced. Moreover, Prescott et al. 30 ; were able to demonstrate that enucleated cells and cell fragments, made from L-cells using cytochalasin B, support vaccinia uncoating and the.
History of Mitomycin
Intrapericardial Cisplatin in Lung Adenocarcinoma 8. Vaitkus PT, Herrmann HC, LeWinter MM: Treatment of malignant pericardial effusion. JAMA 1994; 257: 59-64. Zwischenberger JB, Sanker AB, Lee R: Malignant pericardial effusion, in Pass HJ, Mitchell JB, Johnson DH, Turrisi AT, Minna JD eds ; : Lung cancer. Principles and practice. Lippincott, Philadelphia, 2000; pp 1038-1046. 10. Gebbia V, Galetta D, Caruso M, et al: Gemcitabine and cisplatin versus vinorelbine and visplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma. Lung Cancer 2003; 39 2 ; : 179-189. 11. Tomkowski WZ, Wisniewska J, Szturmowicz M, et al: Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer 2004; 12: 53-57. Maisch B, Ristic AD, Pankuweit S, Neubauer S, Moll R: Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin. Eur Heart J 2002; 23: 625-631. Laham RJ, Cohen DJ, Kuntz RE, Baim DS, Lorell BH, Simons M: Pericardial effusion in patients with cancer: outcome with contemporary management strategies. Heart 1996; 75: 67-71. Levine MJ, Lorell BH, Diver DJ, Come PC: Implications of echocardiographically assisted diagnosis of pericardial tamponade in contemporary medical patients: detection before hemodynamic embarrassment. J Coll Cardiol 1991; 17: 59-65. Singh S, Wann LS, Schucard GH: Right ventricular and right atrial collapse in patients with cardiac tamponade: a combined echocardiographic and hemodynamic study. Circulation 1984; 70: 966-971. Engel PJ, Hon H, Fowler NO, Plummer S: Echocardiographic study of right ventricular wall motion in cardiac tamponade. J Cardiol 1982; 50: 1018-1021. Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky Performance Status Scale: an examination of its reliability and validity in a research setting. Cancer 1984; 53: 2002-2007. Bishiniotis TS, Antoniadou S, Katseas G, Mouratidou D, Litos AG, Balamoutsos N: Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of thiotepa. J Cardiol 2000; 86: 362-364. Colleoni M, Martinelli G, Beretta F: Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol 1998; 16: 2371-2376. Van der Gaast A, Kok TC, Van der Linden NH, Splinter TH: Intrapericardial instillation of bleomycin in the management of malignant pericardial effusion. Eur J Cancer Clin Oncol 1989; 25: 1505-1506. Yano T, Yokohama H, Inoue T, Takanashi N, Asoh H, Ichinose Y: A simple technique to manage malignant pericardial effusion with a local instillation of bleomycin in non-small cell carcinoma of the lung. Oncology 1994; 51: 507-509. Cormican MC, Nyman CR: Intrapericardial bleomycin for the management of cardiac tamponade secondary to malignant pericardial effusion. Br Heart J 1990; 63: 61-62. Norum J, Lunde P, Aasebo U, Himmelmann A: Mitoxanthrone in malignant pericardial effusion. J Chemother 1998; 10: 399-404. Lee NY, Yang PC, Chang DB: Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion. Thorax 1994; 49: 594-595. Primrose WR, Clee MD, Johnston RN: Malignant pericardial effusion managed with vinblastine. Clin Oncol 1983; 9: 67-70. Lissoni P, Barni S, Tancini G: Intracavitary therapy of neoplastic effusions with cytokines. Support Care Cancer 1995; 3: 78-80. Inamura T, Tamura K, Takenaga M, Nagamoto Y, Ishikawa T, Nakagawa S: Intrapericardial OK-432 instillation for the management of malignant pericardial effusion. Cancer 1991; 68: 259-263. Davis S, Rambotti P, Grignani F: Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases. J Clin Oncol 1984; 2: 631-636. Maher EA, Shepherd FA, Todd TJ: Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 1996; 112: 637-643. Salamon P, Berniner S, Shachner A, Pinkhas J: Tetracycline treatment for malignant pericardial effusion. Med Interne 1989; 27: 73-74. Shepherd FA, Ginsberg JS, Evans WK, Scott JG, Oleksiuk F: Tetracycline sclerosis in the treatment of malignant pericardial effusion. J Clin Oncol 1985; 3: 1678-1682. Shepherd FA, Morgan C, Evans WK, Ginsberg JF, Watt D, Murphy K: Medical management of malignant pericardial effusion by tetracycline sclerosis. J Cardiol 1987; 60: 11611166. Gatt NG, Pagliuka A, Mufti GJ: Colchicine: an effective treatment for refractory malignant pericardial effusion. Acta Haematol 2000; 104: 217-219. Sprengelmeyer JT, McDermott RL: Phosphorus-32-colloidal chromic phosphate: treatment of choice for malignant pericardial effusion. J Nucl Med 1990; 31: 2034-2036. Fiorentino MV, Daniele O, Morandi P: Intrapericardial instillation of platin in malignant pericardial effusion. Cancer 1988; 62: 1904-1906. Tondini M, Rocco G, Bianchi C, Severi C, Corbellini D: Intracavitary cisplatin CDDP ; in the treatment of metastatic pericardial involvement from breast and lung cancer. Monaldi Arch Chest Dis 1995; 50: 86-88. Lestuzzi C, Viel E, Sorio R, Meneguzzo N: Local chemotherapy for neoplastic pericardial effusion. J Cardiol 2000; 86: 1292. Tamura A, Matsubara O, Yoshimura N: Cardiac metastases of lung cancer. Cancer 1992; 70: 437-442.
Mitomycin prices
A series of trials have involved the use of mitomycin C MMC; Mutamycin; Bristol-Myers Squibb ; Table 1 ; . A Spanish trial investigated the use of single-agent, high-dose MMC following surgical resection [7]. In that study, only 33 patients received chemotherapy MMC, 20 mg m 2 once every 6 weeks for four doses ; , while 37 patients constituted the control group. A significant survival advantage seven relapses in the treated arm, 23 in the control arm; p .001 ; for the chemotherapy group was noted [7]. Consequently, Grau et al. performed a randomized trial on 134 patients using the same regimen [8]. After a median follow-up of 105 months, the actuarial survival curve was significantly p .025 ; higher in the treatment group. Allum and coworkers investigated 411 patients in a prospective, randomized trial using a more complex polychemotherapy regimen [9]. After a follow-up of at least 5.5 years there has been no survival advantage for patients receiving adjuvant 5-FU and MMC with or without an induction course of 5-FU, vincristine Oncovin; Eli Lilly and Company, Indianapolis ; , cyclophosphamide, and methotrexate compared with those undergoing surgery only. Chemotherapy was not tolerated well and toxicities were substantial, resulting in 22 treatment-related deaths. To determine whether postoperative adjuvant chemotherapy with two drugs versus one drug could prolong survival, Grau et al. investigated 85 patients with completely.
784 operative i.p. chemotherapy without hyperthermia ; , or with nonoptimal IPCH phase I trial to define the best technique to perform IPCH ; [4, 16]. More interesting are the preliminary results of the randomized trial of Zoetmulder et al. comparing standard treatment systemic chemotherapy ; to cytoreductive surgery with IPCH using mitomycin C in 104 colorectal patients. The 2-year survival rate in each group was, respectively, 16% and 43% P 0.01 ; , while many patients in the treated group could not benefit from a complete resection of their PC [23]. This phase III study definitively demonstrated the superiority of this new approach. It also underlined the fact that a complete cytoreductive surgery is possible in only some patients with colorectal PC. In our study, the impossibility of resecting all tumor nodules 2 mm was a criteria of exclusion, because IPCH acts only in superficial tissues [5]. Besides, only one of the 24 patients had residual tumor nodules measuring between 1 and 2 mm. Currently, IPCH, which is an aggressive treatment, is indicated to treat only a millimetric residual disease after maximal cytoreductive surgery. Nevertheless, mitomycin C which is used extensively worldwide for IPCH ; is not considered a very active drug for colorectal cancers, unlike LOHP [24, 25]. It was therefore logical to use LOHP for IPCH. We thus conducted a first trial in humans to study the pharmacokinetics of heated i.p. LOHP in order to define the suitable dosage and tolerance [17]. The dose used in the present study and the addition of i.v. 5-FU and LV represent the direct application of our results. Half the dose of i.p. LOHP was absorbed in 30 min, and tumoral tissue concentration of LOHP was 18-fold higher in bathed tissues than in non-bathed ones [17]. We did not use any hypotonic solution in our study, because we demonstrated in another human trial that it had no pharmacokinetic advantage and frequently resulted in local postoperative hemorrhage [18]. When looking at prognostic factors, a peritoneal index 24 could be a new and promising one: in our series, only one of the six patients with such a score did not recur. This leads to the hypothesis that, maybe in the future, the presence of liver metastases and or a peritoneal index 24 could represent a relative contraindication to this approach. However, more extensive data are necessary to confirm these findings. The efficacy of peritoneal mixing can still be improved because polychemotherapies are more potent than monotherapies. This is the reason why we are currently conducting a phase I trial combining LOHP with irinotecan during IPCH in humans. However, at this date, our biggest challenge is to select the right patients for this approach: it is necessary to detect infraclinic extraperitoneal disease and also to appreciate the real extent of the PC before operating. In conclusion, IPCH with LOHP, after complete resection of PC, gave encouraging therapeutic results and is able to cure definitively a high proportion of selected patients and mitotane.
Mitomycin ointment
CONCLUSION No increase in the incidence of SCEs at any dose level with or without m SYSTEM OF TESTING - test procedure without MA: cells exposed to the TS for 2 hrs without addition of BrdU; than BrdU was added and exposure continued for 24 hrs; after washing cells incubated in medium containing BrdU and colcemid for 2-3 hrs; cells were then harvested by the mitotic shake-off method, fixed and stained with Hoechst 33258 and Giemsa; 50 second metaphase cells per dose scored for SCEs. - test procedure with MA: incubation with S9-mix plus TS for 2 hrs without fetal calf serum; then cells incubated in medium containing BrdU and 10% fetal calf serum no TS ; for 26 hrs, with colcemid present the last 2-3 hrs; further preparation see above. - Metabolic activation MA ; system: S9-mix, liver microsomes prepared from male Sprague-Dawley rats treated with Aroclor1251 - number of chromosomes examined: ca. 1050 per dose level, - Solvent: supplemented McCoy's 5A medium culture medium ; - Controls: negative solvent control ; positive control mitomycin C without MA ; or cyclophosphamide with MA ; - one trial performed - laboratory: Environmental Health Research & Testing CRITERIA FOR EVALUATING RESULTS: - no data - 77 125.
Background: Peritoneal dissemination of appendiceal malignancy combined with regional lymph node metastasis is an unusual combination of patterns of cancer dissemination. Methods: A database of 501 appendiceal malignancy patients, all with documented peritoneal seeding, was used to identify 25 patients with involvement of the regional lymph nodes. All patients were uniformly treated with cytoreductive surgery plus perioperative intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil. The clinical and pathologic features of the lymph nodepositive patients were compared with those of the lymph nodenegative patients. The effect of regional lymph node involvement on survival was determined. Within the group of lymph nodepositive patients, clinical and pathologic features were tested for their effect on survival. Results: When compared with patients with no apparent lymph node positivity, patients with positive lymph nodes were more likely to have an acute abdomen as the initial presentation P .001 ; . The intestinal nonmucinous ; histological type was more common P .001 ; , and the disseminated peritoneal adenomucinosis histology was less common P .001 ; . Survival with the aggressive treatment strategy used in these patients was not different for lymph nodepositive as compared with lymph nodenegative patients P .15 by univariate and P .38 by multivariate analysis ; . Conclusions: Appendiceal malignancy with dissemination to the lymph nodes has a more acute onset and a more frequent nonmucinous histology. With aggressive treatment strategies, lymph nodepositive patients did not show a statistically significantly diminished survival. Key Words: Appendix neoplasms--Pseudomyxoma peritonei--Mucinous adenocarcinoma and modafinil.
Mitomycin medicine
Tervals by the Cancer Chemotherapy National Serv ice Center. National institutes of Health, Bethesda, Md. 4. Coisky, J.; Escher, 0. C.; Evans, A.; Mit us, A.; Li 1 ; Booth, S.; Smmllivan, R. D.; Sykes, .11. P., C and Tan, C. T. C.: Preliminary clinical pharmacol ogy of Mitomycin C. Proc. Am. A. Cancer Res. 3: 13, 1959. Creech, 0., Jr.; Ryan, R. F., and Krementz, E. T.: Treatment of melamioma by isolation-perfuskni tech muiqmme. A. 31. A. 169 : 339-343, 1959. J. 6. Curreri, A. R.; Ansfield, F. J.; Mclver, F. A.
Conclusion Orlistat as an adjunct to dietary intervention promotes clinically significant weight loss and LDL-C beyond the effect of weight loss in overweight or obese patients with concomitant hypercholesterolemia. Run-in weight loss and weight loss during the first 4 weeks were predictors of longer-term weight loss at 24 weeks and modicon.
The development of drug resistance was found to be associated to the higher expression of P-Gp, similar to the MDR human SCLC cells 18 ; and the CHRC5 MDR subline 6 ; . Most of the strategies used to treat multidrug resistance associated to P-Gp involve the efflux inhibition provoked by this membrane pump 5, 16 ; . VRP partially reversed resistance to vinblastine, vincristine and mitomycin C exhibited by HCA-2 1cch cells, obtaining a remarkably higher reversal for the selection drug. This could be due to the fact that colchicine has less affinity for P-Gp than the rest of the drugs which is why it might be recognised and transported out of cells less effectively 19 ; . In other studies, verapamil favours the effect of cytotoxic drugs on murine lung carcinoma, melanoma and human colon adenocarcinoma 15 ; . HLLT et al. 5 ; have found that incubation with 1 g ml VRP is sufficient to increase 13-18 times the cytotoxicity of VBL and other authors 19 ; state that VRP doses of 1.62 and 3.24 g ml produce a relative sensitisation rates from 1.4 to 7.5 for VCR and 1 to 8 for CCH. Chemosensitisation is a complex and multifactorial process, which could depend on the cytotoxic drugs, the type of sensitiser and the dose used, as well as on the quantity of P-Gp expressed by the cell line.
Reference Values Leukocyte alkaline phosphatase Periodic acidSchiff stain 13130 U Granulocytes--positive Agranulocytes--negative Granulocytic precursors--negative Erythrocytes--negative Erythrocytic precursors--negative Tartrate-resistant acid phosphatase found in neutrophils. This enzyme is completely independent of serum alkaline phosphatase, which reflects osteoblastic activity and hepatic function. The LAP content of neutrophils increases as the cells mature; therefore, the LAP study is useful in assessing cellular maturation and in evaluating departures from normal differentiation. The LAP study is used to distinguish among various hematologic disorders. For example, LAP increases in polycythemia vera, myelofibrosis, and leukemoid reactions to infections, but decreases in chronic granulocytic leukemia. Because all of these conditions have increased numbers of immature circulating neutrophils, LAP scores can be helpful in differentiating among them and molindone.
Mitomycin and fluorouracil
To assist in the execution of its responsibilities, the Board has established a number of Board Committees including an Audit and Compliance Committee, Compensation and Nomination Committee, Share Issue Committee and a Standing Committee for Urgent Matters. Towards the end of the year, an Occupational Health, Safety and Environment Committee was also established by the Board. These committees have written terms of reference which are reviewed on a regular basis. Audit and Compliance Committee This Committee is responsible for providing a link between the external auditors of Mayne and the Board. It reviews financial statements for accuracy, to ensure they reflect a true and fair view, and for adherence to accounting standards and policies. The Committee reviews accounting policies adopted or any changes made or contemplated, and is also responsible for reviewing the plans, results and effectiveness of the external and internal audit programs. In addition.
The data shown in Table 1 were obtained under conditions in which the host cells had been exposed to tomycin prior to the addition of virus. The presence of Mitomycin throughout the experiment did not affect the results, however, as is seen from the data in Table 2 and moxifloxacin.
Traditional `pure' statistical machine translation SMT ; systems1 have had limited success in the past, due to the fact that such systems do not use any explicit linguistic knowledge. This relative failure has led to the more recent development of hybrid SMT systems, incorporating linguistic information e.g. structural information ; to improve translation quality. Data-oriented translation DOT ; 3 is one such hybrid approach to the translation problem. DOT comprises a context-rich, experience-based approach to translation, where new translations are derived with reference to grammatical analyses of previous translations. In order to produce high-quality translations a DOT system requires large sets of data, consisting of phrase-structure PS ; tree representations of sentences in both languages aligned at a sentential and sub-sentential level. Previously this sub-sentential alignment was performed manually, which is a time-consuming and error-prone task. It also requires considerable knowledge of both the source and target languages as well as how they are related. For a DOT system to be feasibly used on other language pairs this tree alignment needs to be performed automatically. Thus far my research has focused on the development of a program for aligning PS trees at a subsentential level. The aligner has been applied to sub-sections of the English-French, English-German and French-German sections of the HomeCentre corpus. The aligned data has then been used as input into the DOT system and a number of experiments and evaluations have been carried out. The results of the experiments to date have been extremely promising, proving the automatic alignment constitutes a viable alternative to manual alignment2. For future work I plan to investigate the development of a syntax-based SMT system, using the treealigner in the modelling of structural information, along with probabilistic context-free grammars and example-based machine translation resources in the estimation of the system's language and translation models.
Mitomycin vs bcg
Mitomycin bladder cancer side effects
Joint security area, referred pain more tests_diagnosis, diagnosis 90807, hepatitis c organizations and mohs surgery blog. Birth control effectiveness rates, forceps butterfly fish, pigment transfer and anesthetist technician training or diabetes mellitus and hypertension.
Mitomycin children
Mitomcin, mittomycin, mitlmycin, mitomjcin, mi6omycin, mitomyciin, miotmycin, mitomycinn, mitomycni, mitomyycin, mitomyvin, mktomycin, miomycin, miromycin, mitomtcin, mifomycin, mitonycin, mitomycjn, mitojycin, mitomycon.
Mitomycin bladder installation
History of mitomycin, mitomycin prices, mitomycin ointment, mitomycin medicine and mitomycin and fluorouracil. Mitomycin vs bcg, mitomycin bladder cancer side effects, mitomycin children and mitomycin bladder installation or mitomycin eye surgery.
|